Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
The High Court ruled on a significant patent dispute involving Pfizer and GSK, addressing costs and confidentiality.
We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...
Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...
is Rs 1842.05 Glaxosmithkline Pharmaceuticals Ltd, incorporated in the year 1924, has its registered office in GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030, 91-022-24959595 ...
We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST. GSK said in a statement that it had agreed ...
In a deal that could potentially be worth up to US$820 million, GlaxoSmithKline (GSK) has gained the exclusive, worldwide development and commercialization rights to retigabine, a first-in-class ...
Teva Pharmaceutical Industries Ltd. ADR 1.11% $24.97B ...